Ergomed PLC Stock Is Rising Now

 Ergomed PLC Stock Is Rising Now

The stock of Ergomed PLC (LON:ERGO) is a huge mover today! The stock increased 3.25% or GBX 4.3 on November 29, hitting GBX 136.8. About 27,833 shares traded hands or 1.94% up from the average. Ergomed PLC (LON:ERGO) has declined 9.25% since April 29, 2016 and is downtrending. It has underperformed by 14.51% the S&P500.
The move comes after 9 months positive chart setup for the GBX 54.35 million company. It was reported on Nov, 29 by Barchart.com. We have GBX 145.01 PT which if reached, will make LON:ERGO worth GBX 3.26 million more.

Ergomed PLC (LON:ERGO) Ratings Coverage

Out of 3 analysts covering Ergomed (LON:ERGO), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ergomed has been the topic of 17 analyst reports since September 29, 2015 according to StockzIntelligence Inc. Stifel Nicolaus maintained the shares of ERGO in a report on Monday, February 1 with “Buy” rating. The firm has “Buy” rating given on Tuesday, October 13 by N+1 Singer. N+1 Singer maintained the stock with “Buy” rating in Tuesday, September 29 report. The stock of Ergomed PLC (LON:ERGO) earned “Buy” rating by Numis Securities on Tuesday, November 1. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, November 1. On Wednesday, December 16 the stock rating was maintained by N+1 Singer with “Buy”. The stock has “Buy” rating given by Stifel Nicolaus on Wednesday, October 21. The stock of Ergomed PLC (LON:ERGO) earned “Buy” rating by N+1 Singer on Friday, October 21. N+1 Singer maintained Ergomed PLC (LON:ERGO) rating on Monday, November 7. N+1 Singer has “Buy” rating and GBX 275 price target. N+1 Singer maintained Ergomed PLC (LON:ERGO) on Tuesday, November 1 with “Buy” rating.

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The company has a market cap of 54.35 million GBP. The Firm operates through two divisions: clinical research services , and drug safety and medical information services (DS&MI). It has a 30.31 P/E ratio. It provides a range of clinical trial planning, management and monitoring services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment